GSK’s Blenrep has pivotal clinical trial results showing the multiple myeloma therapy reduced the risk of disease progression or death by nearly 50%. The results were presented Sunday during the annual meeting of the America Society of Clinical Oncology.

The post GSK’s Quest to Bring Myeloma Drug Back to the Market Stops for a Data Drop at ASCO appeared first on MedCity News.

Gilead Sciences reported Trodelvy’s Phase 3 test in metastatic urothelial cancer fell short of showing a statistically significant benefit on the overall survival main goal. The antibody drug conjugate had received accelerated FDA approval for this type of cancer in 2021.

The post Gilead Sciences ADC Flunks Its Confirmatory Test in Advanced Bladder Cancer appeared first on MedCity News.

The Singapore manufacturing site will be AstraZeneca’s first facility capable of handling all steps of antibody drug conjugate production. AstraZeneca aims to open the facility in 2029.

The post AstraZeneca Plans $1.5B Manufacturing Site for Global Production of ADC Cancer Drugs appeared first on MedCity News.

Enlaza Therapeutics’ drugs form covalent bonds that lock the therapy onto its target. With cancer as its initial focus, the startup contends its approach could offer safety and efficacy advantages compared to currently available targeted therapies.

The post J.P. Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer appeared first on MedCity News.

Torl BioTherapeutics’ $158 million Series B-2 financing will finance clinical testing of its pipeline of antibody drug conjugates in development for various types of cancer. Neuroscience and immunology are among the therapeutic areas represented in our roundup of other recent biotech financings.

The post Another ADC Developer Lands a Mega Round of Financing for Cancer Clinical Trials appeared first on MedCity News.

The FDA expanded Enhertu’s approval to encompass advanced solid tumors positive for the HER2 cancer protein, regardless of tumor type. Analysts say the regulatory decision paves the way for similar broader approvals of other medications in the ADC cancer drug class.

The post AstraZeneca, Daiichi Sankyo Drug Enhertu Becomes First Tumor-Agnostic ADC Cancer Med appeared first on MedCity News.

Antibody specialist Genmab makes most of its money from drugs developed and commercialized by partners. Acquiring ProfoundBio brings antibody drug conjugates that Genmab can develop on its own as it continues diversifying its business beyond strategic alliances.

The post Genmab Adds More ADC Firepower With $1.8B ProfoundBio Acquisition appeared first on MedCity News.

Ipsen is acquiring global rights to a Sutro Biopharma antibody drug conjugate for a target that is not yet hit by any FDA-approved drugs. Merck is among the companies pursuing this target, but Sutro claims its ADC could be first and best in this class.

The post Ipsen Joins the ADC Chase, Licensing Phase 1-Ready Asset for Novel Cancer Target appeared first on MedCity News.

Tubulis’s next-generation ADC cancer drugs are designed to overcome limitations of currently available therapies in this drug class. The new financing will support clinical trial plans, but first, preclinical proof-of-concept data will be presented during the American Association for Cancer Research annual meeting.

The post A Startup’s Flexibility With ADC Cancer Drugs Attracts €128M for Clinical Trials appeared first on MedCity News.

Versant Ventures-backed Firefly Bio is part of a growing group of companies developing degrader antibody conjugates, or DACs. These targeted cancer therapies combine properties of antibody drug conjugates and protein degraders in order to overcome limitations of both types of therapies.

The post Firefly Bio Unveils $94M to Illuminate the Startup’s New Take on ADC Cancer Meds appeared first on MedCity News.

Gilead Sciences said even though Trodelvy missed the main goal of its Phase 3 test in non-small cell lung cancer, the drug’s preliminary results show numerical improvement in patients whose disease did not respond to prior treatment with immunotherapy. The company plans to discuss with regulators a possible path forward in these patients.

The post Gilead Drug Fails Pivotal Lung Cancer Study, But Still Might Have Path Forward appeared first on MedCity News.

Though GSK divested much of its oncology assets to Novartis in 2015, the company has built back through a internal R&D and business development deals. GSK Senior Vice President, Global Head of Oncology, R&D Hesham Abdullah explained the company’s evolving cancer strategy in an interview during the J.P. Morgan Healthcare Conference in San Francisco.

The post At JPM, Top GSK Cancer Executive Talks Drug Targets and Oncology Strategy appeared first on MedCity News.

Johnson & Johnson’s acquisition of antibody drug conjugate developer Ambrx Biopharma comes as Novartis and Merck also unveiled M&A deals on the first day of the J.P. Morgan Healthcare conference. In a report, the bank said big pharmas are looking for deals involving de-risked assets.

The post J&J Joins the Cancer ADC Dealmaking Spree With $2B Ambrx Acquisition appeared first on MedCity News.

GSK gains rights to a Hansoh Pharma antibody drug conjugate that targets a protein abundant on lung cancer cells and other types of solid tumors. The pharmaceutical giant plans to start its own slate of clinical trials with this ADC in 2024.

The post GSK Expands Again in Cancer, Paying Hansoh $185M for Another ADC appeared first on MedCity News.

AbbVie announced plans to acquire Immunogen — and the biotech’s recently approved ADC treatment for ovarian cancer — for $10.1 billion in cash. The pharma giant is diving into ADCs again after a previous multibillion-dollar acquisition of a different ADC drugmaker ended up failing a few years ago.

The post AbbVie Tries Its Hand at ADCs Again With $10.1B Immunogen Acquisition appeared first on MedCity News.

Bristol Myers Squibb is expanding its scope in cancer by acquiring rights to a Phase 1-ready Orum Therapeutics program that brings a new twist to antibody drug conjugates. The deal is the latest business development move in the hot field of ADCs.

The post BMS Pays $100M for Next-Gen Orum Therapeutics ADC for Blood Cancers appeared first on MedCity News.

After paying $4 billion up front, Merck will share in the development and commercialization of three Daiichi Sankyo cancer drugs in the red-hot field of antibody drug conjugates, or ADCs. The most advanced of them is on track for an FDA submission in 2024.

The post Merck Missed on Seagen, But Comes Back With Potential $22B Daiichi ADC Deal appeared first on MedCity News.

BioNTech gains rights to a MediLink Therapeutics antibody drug conjugate that targets tumors expressing the HER3 protein. The deal comes six months after the German company entered the ADC field by acquiring rights to two therapeutic candidates from DualityBio.

The post BioNTech Turns to China Again for Cancer Drugs, Paying $70M to Partner on an ADC appeared first on MedCity News.

Seagen and Nurix are bringing their respective technologies together to develop a new class of cancer drugs called degrader antibody conjugates. Nurix CEO Arthur Sands says the multi-year, multi-target collaboration expands the reach of each company’s technology.

The post Seagen and Nurix Join Forces to Develop a New Class of Cancer Medicines appeared first on MedCity News.

An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies disclosed few details about them.

The post AstraZeneca, Daiichi Cancer Drug’s Phase 3 Results Clouded by Toxicity Concerns appeared first on MedCity News.

Eisai gains an option to license a Bliss Biopharmaceutical drug that targets HER2, a cancer protein that has become a hot target for addressing several types of solid tumors. BlissBio could receive up to $2 billion in milestones and other payments.

The post Eisai Strikes Cancer Alliance to Line Up Potential Challenger to AstraZeneca Drug appeared first on MedCity News.

BioNTech’s alliance with DualityBio gives it two antibody drug conjugate (ADC) candidates, the most advanced of which is in mid-stage clinical development for solid tumors. It addresses the same target as a potential blockbuster AstraZeneca drug.

The post BioNTech Buys Into Hot Area of Cancer R&D, Paying $170M for 2 Drug Assets appeared first on MedCity News.

Pfizer is no stranger to antibody drug conjugate cancer therapies, but it hasn’t been commercially successful with them. The pharma giant’s agreement to acquire Seagen for $43 billion will thrust it to the forefront of the ADC drug class, which has become a hot space for research and regulatory activity in recent years.

The post Pfizer’s Seagen Acquisition Brings It Full Circle in a Hot Area of Cancer Drug R&D appeared first on MedCity News.

We now see the next wave of potential cancer therapies on the horizon, propelled by significant advancements in immunology, as well as an increased understanding of tumor-driven mechanisms of immune evasion.

The post A multifaceted approach to improve cancer treatment and care appeared first on MedCity News.

Jazz Pharmaceuticals is paying Zymeworks $50 million up front for rights to develop zanidatamab, a bispecific antibody cancer currently in two pivotal clinical trials. It’s the second bispecific antibody pact of the week, following Gilead Sciences’ deal to secure an option on a MacroGenics drug in early clinical development.

The post Jazz Pharma joins the bispecific cancer drug chase via Zymeworks licensing deal appeared first on MedCity News.

Gilead Sciences said it has statistically significant and clinically meaningful data from a pivotal test of its cancer drug, Trodelvy, in the most common type of breast cancer. While detailed data remain undisclosed, the company said it has filed a submission with the FDA seeking to expand the drug’s approval to include this larger group of breast cancer patients.

The post Gilead claims breast cancer trial win but offers few details; drug application is filed with FDA appeared first on MedCity News.

GSK is partnering with Mersana Therapeutics on the development of an antibody-drug conjugate that is approaching Phase 1 testing. Unlike other ADCs that deliver a toxic drug payload, the Mersana drug is designed to activate the innate immune system to fight tumor cells.

The post GSK pays $100M to partner on a cancer drug with new twist on immunotherapy appeared first on MedCity News.

Astellas Pharma has a new partner in the R&D of a type of cancer drug called an antibody drug conjugate (ADC). The Japanese pharma company reached across the Pacific Ocean to collaborate with Sutro Biopharma in a bet that Bay Area-based firm’s technology can deliver more powerful ADCs.

The post Astellas pays Sutro Bio $90M to partner on cancer drugs that make cold tumors hot appeared first on MedCity News.

During the annual meeting of the American Society of Clinical Oncology, AstraZeneca and Daiichi Sankyo reported pivotal clinical trial data showing that their partnered cancer drug Enhertu can treat a group of patients previously thought to be out of reach for a targeted therapy. The results suggest use of this FDA-approved drug could significantly expand to more breast cancer patients.

The post AstraZeneca, Daiichi Sankyo have high hopes for drug that goes low in breast cancer appeared first on MedCity News.

Antibody drug conjugates have made scientific and regulatory progress in recent years. Sanofi is partnering with ADC specialist Seagen in a multi-drug alliance that keeps the pharmaceutical giant in the mix of this growing field of cancer therapies.

The post Sanofi and Seagen team up to grow a new crop of ADC cancer drugs appeared first on MedCity News.